omeprazole has been researched along with Sensitivity and Specificity in 115 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the clinical value of an empirical trial of high-dose lansoprazole in detecting patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 9.11 | The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. ( Bautista, J; Briseno, M; Cui, H; Fass, R; Fullerton, H, 2004) |
| "Therapeutic trials with high-dose lansoprazole and omeprazole have been shown to be sensitive clinical tools for diagnosing patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 9.11 | The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. ( Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J, 2005) |
| "Eighteen men and 24 women, aged 22 to 77 years, who presented with recurrent chest pain complaints of a noncardiac etiology, as determined by rest/stress perfusion imaging with technetium Tc99m sestamibi (MIBI), were enrolled in a prospective, double-blinded, placebo-controlled, crossover trial using high-dose omeprazole." | 9.10 | Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. ( Arezo, S; Crofts, T; DeCosta, G; Everett, S; Gennings, C; Jesse, R; Pandak, WM; Siuta, M; Zfass, A, 2002) |
| "To evaluate the diagnostic accuracy of a trial of a high-dose proton pump inhibitor (the omeprazole test) in detecting gastroesophageal reflux disease (GERD) in patients with heartburn symptoms." | 9.09 | Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. ( Camargo, E; Fass, R; Fennerty, MB; Gralnek, IM; Johnson, C; Ofman, JJ; Sampliner, RE, 1999) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 9.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| "Determination of the symptomatic response to 40 mg of omeprazole for 14 days is a simple and inexpensive tool for the diagnosis of GERD, with a sensitivity and specificity comparable to 24-h pH monitoring." | 9.08 | Omeprazole as a diagnostic tool in gastroesophageal reflux disease. ( Dieleman, LA; Festen, HP; Jansen, EH; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE; Schrijver, M; Tuynman, HA, 1997) |
| " The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations." | 9.08 | The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. ( Camargo, E; Fass, R; Fennerty, MB; Gralnek, IM; Johnson, C; Ofman, JJ; Sampliner, RE, 1998) |
| "Recent evidence suggests that an empiric trial of omeprazole (the "omeprazole test") is sensitive and specific for diagnosing gastroesophageal reflux disease (GERD) as the cause of noncardiac chest pain." | 7.70 | The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. ( Fass, R; Fennerty, MB; Gralnek, IM; Ofman, JJ; Udani, J, 1999) |
| "To compare the omeprazole test to ambulatory 24-h oesophageal pH monitoring in diagnosing GERD in symptomatic patients using endoscopically proven erosive oesophagitis as a gold standard." | 7.70 | The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. ( Camargo, L; Fass, R; Fennerty, MB; Ofman, JJ; Sampliner, RE; Wendel, C, 2000) |
| "Paraffin-embedded and haematoxylin-eosin-stained sections of biopsy material obtained from patients taking omeprazole reveal a characteristic "hypertrophy" of the parietal cells; these are taller than the chief cells, and project, with convexly bulging apical cell membrane, into the lumen of the body glands, producing a serrated internal gland profile." | 7.68 | Omeprazole-induced pseudohypertrophy of gastric parietal cells. ( Bethke, B; Ritter, M; Rühl, G; Stolte, M, 1992) |
| "The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test." | 6.72 | Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. ( Aygalenq, P; Bonnot-Marlier, S; des Varannes, SB; Galmiche, JP; Le Rhun, M; Lequeux, Y; Masliah, C; Sacher-Huvelin, S; Vavasseur, F, 2006) |
| " Furthermore, the data indicate that 1-week treatment with a once-daily dosage is sufficient to ensure adequate diagnosis." | 6.71 | One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. ( Edin, R; Falk, A; Hatlebakk, JG; Johnsson, F; Klintenberg, AC; Román, J; Stubberöd, A; Toth, E, 2003) |
| "Symptoms of gastro-oesophageal reflux are common, and currently available methods for diagnosing reflux disease are expensive and uncomfortable for the patient." | 6.69 | One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. ( Bengtsson, L; Hernqvist, H; Johnsson, F; Solhaug, JH; Weywadt, L, 1998) |
| "Both omeprazole and endoscopy were compared to pH monitoring as the 'gold standard' for the diagnosis of GERD and the cost per correct diagnosis with omeprazole was pound47 (95% CI: pound40- pound59) compared to pound480 (95% CI: pound396- pound608) with endoscopy." | 5.30 | Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. ( Bate, CM; Chapman, RW; Durnin, AT; Riley, SA; Taylor, MD, 1999) |
| "To determine the clinical value of an empirical trial of high-dose lansoprazole in detecting patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 5.11 | The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. ( Bautista, J; Briseno, M; Cui, H; Fass, R; Fullerton, H, 2004) |
| "Therapeutic trials with high-dose lansoprazole and omeprazole have been shown to be sensitive clinical tools for diagnosing patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 5.11 | The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial. ( Cui, H; Dickman, R; Emmons, S; Esquivel, RF; Fass, R; Hernández, D; Sewell, J, 2005) |
| "Eighteen men and 24 women, aged 22 to 77 years, who presented with recurrent chest pain complaints of a noncardiac etiology, as determined by rest/stress perfusion imaging with technetium Tc99m sestamibi (MIBI), were enrolled in a prospective, double-blinded, placebo-controlled, crossover trial using high-dose omeprazole." | 5.10 | Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. ( Arezo, S; Crofts, T; DeCosta, G; Everett, S; Gennings, C; Jesse, R; Pandak, WM; Siuta, M; Zfass, A, 2002) |
| "To evaluate the diagnostic accuracy of a trial of a high-dose proton pump inhibitor (the omeprazole test) in detecting gastroesophageal reflux disease (GERD) in patients with heartburn symptoms." | 5.09 | Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. ( Camargo, E; Fass, R; Fennerty, MB; Gralnek, IM; Johnson, C; Ofman, JJ; Sampliner, RE, 1999) |
| " Fifty patients with active or scarred duodenal ulcer were randomized to lansoprazole or omeprazole for 1 to 4 weeks, with clarithromycin 250 mg twice a day and tinidazole 500 mg twice a day for the first week." | 5.09 | Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer. ( Fanti, L; Guslandi, M; Ieri, R; Mezzi, G; Passaretti, S; Testoni, PA, 2001) |
| "Determination of the symptomatic response to 40 mg of omeprazole for 14 days is a simple and inexpensive tool for the diagnosis of GERD, with a sensitivity and specificity comparable to 24-h pH monitoring." | 5.08 | Omeprazole as a diagnostic tool in gastroesophageal reflux disease. ( Dieleman, LA; Festen, HP; Jansen, EH; Klinkenberg-Knol, EC; Kuipers, EJ; Meuwissen, SG; Schenk, BE; Schrijver, M; Tuynman, HA, 1997) |
| " The aim of this study was to evaluate the efficacy of the omeprazole test (OT) in diagnosing gastroesophageal reflux (GERD) in patients with NCCP and estimate the potential cost savings of this strategy compared with conventional diagnostic evaluations." | 5.08 | The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. ( Camargo, E; Fass, R; Fennerty, MB; Gralnek, IM; Johnson, C; Ofman, JJ; Sampliner, RE, 1998) |
| " Symptom relief during treatment with omeprazole was predicted by the presence of heartburn, described as 'a burning feeling rising from the stomach or lower chest up towards the neck' (P = 0." | 3.70 | The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. ( Bolling-Sternevald, E; Carlsson, R; Dent, J; Johnsson, F; Junghard, O; Lauritsen, K; Lundell, L; Riley, S, 1998) |
| "Recent evidence suggests that an empiric trial of omeprazole (the "omeprazole test") is sensitive and specific for diagnosing gastroesophageal reflux disease (GERD) as the cause of noncardiac chest pain." | 3.70 | The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. ( Fass, R; Fennerty, MB; Gralnek, IM; Ofman, JJ; Udani, J, 1999) |
| "To compare the omeprazole test to ambulatory 24-h oesophageal pH monitoring in diagnosing GERD in symptomatic patients using endoscopically proven erosive oesophagitis as a gold standard." | 3.70 | The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. ( Camargo, L; Fass, R; Fennerty, MB; Ofman, JJ; Sampliner, RE; Wendel, C, 2000) |
| "Acid suppressive therapy with omeprazole improves asthma symptoms and/or PEFs by >20% and improves pulmonary function in 73% of asthmatics with gastroesophageal reflux after 3 months of acid suppressive therapy." | 3.69 | Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. ( Alexander, RW; Bradley, LA; Guzzo, MR; Harding, SM; Richter, JE; Schan, CA, 1996) |
| "Paraffin-embedded and haematoxylin-eosin-stained sections of biopsy material obtained from patients taking omeprazole reveal a characteristic "hypertrophy" of the parietal cells; these are taller than the chief cells, and project, with convexly bulging apical cell membrane, into the lumen of the body glands, producing a serrated internal gland profile." | 3.68 | Omeprazole-induced pseudohypertrophy of gastric parietal cells. ( Bethke, B; Ritter, M; Rühl, G; Stolte, M, 1992) |
| "The diagnosis of GERD was established on the presence of mucosal breaks at endoscopy and/or an abnormal esophageal 24-h pH test." | 2.72 | Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting. ( Aygalenq, P; Bonnot-Marlier, S; des Varannes, SB; Galmiche, JP; Le Rhun, M; Lequeux, Y; Masliah, C; Sacher-Huvelin, S; Vavasseur, F, 2006) |
| " Both drugs induced similar false-negative UBTs on day 14 of dosing (P = 0." | 2.71 | Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test. ( Biagini, R; Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansi, C; Mele, MR; Savarino, V; Tessieri, L; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "In subjects with gastro-oesophageal reflux disease treated with a proton pump inhibitor, the value of the integrated gastric acidity can predict the likelihood of pathological oesophageal reflux." | 2.71 | Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor. ( Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| " Furthermore, the data indicate that 1-week treatment with a once-daily dosage is sufficient to ensure adequate diagnosis." | 2.71 | One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease. ( Edin, R; Falk, A; Hatlebakk, JG; Johnsson, F; Klintenberg, AC; Román, J; Stubberöd, A; Toth, E, 2003) |
| "Symptoms of gastro-oesophageal reflux are common, and currently available methods for diagnosing reflux disease are expensive and uncomfortable for the patient." | 2.69 | One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. ( Bengtsson, L; Hernqvist, H; Johnsson, F; Solhaug, JH; Weywadt, L, 1998) |
| "We examined 27 patients with hypochlorhydria or achlorhydria based on a predefined basal acid output (BAO) measurement of less than 5." | 1.39 | Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. ( Metz, DC; Shah, P; Singh, MH; Yang, YX, 2013) |
| " The present method was successfully applied to a chiral pharmacokinetic study of omeprazole in human volunteers with different CYP2C19 genotypes." | 1.37 | Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes. ( Shiohira, H; Tateishi, T; Uno, T; Yasui-Furukori, N, 2011) |
| " The method is simple, rapid and rugged, and has been applied successfully to sample analysis in support of a drug-drug interaction study." | 1.36 | Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions. ( Bertelsen, K; Guo, P; Han, F; Huang, MQ; Lin, ZJ; Weng, N; Zhang, W; Zhao, H, 2010) |
| "Tenatoprazole was extracted from a small aliquot of plasma (100 microl) by one-step extraction using hexane-dichloromethane-isopropanol (20:10:1, v/v/v) as extract solvent." | 1.35 | Determination of tenatoprazole enantiomers and their enantioselective pharmacokinetics in rats. ( Guan, J; Li, F; Li, J; Li, X; Yang, J, 2009) |
| " This novel method has been applied to a pharmacokinetic study of OPZ in humans." | 1.35 | Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study. ( Bharathi, DV; Ganneboina, R; Hotha, KK; Layek, B; Mullangi, R; Trivedi, RK; Vittal, S, 2009) |
| "Omeprazole was also analysed in pharmaceutical formulations." | 1.35 | Analysis of omeprazole and its main metabolites by liquid chromatography using hybrid micellar mobile phases. ( Carda-Broch, S; Esteve-Romero, J; Rambla-Alegre, M, 2009) |
| " The developed assay method was applied to a pharmacokinetic study in human volunteers." | 1.35 | Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study. ( Bharathi, DV; Chatki, PK; Hotha, KK; Jagadeesh, B; Mullangi, R; Naidu, A; Thriveni, K, 2009) |
| " This method developed can be easily applied to the pharmacokinetic study of tenatoprazole in dog plasma after oral administration of an enteric-coated capsule." | 1.34 | HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule. ( Li, F; Liu, P; Lu, X; Qin, F; Sun, B, 2007) |
| " This validated method is simple and repeatable enough to be used in pharmacokinetic studies." | 1.34 | Quantification of tenatoprazole in rat plasma by HPLC: validation and its application to pharmacokinetic studies. ( Bhyrapuneni, G; Kandikere, V; Mudigonda, K; Nirogi, R, 2007) |
| "Omeprazole pretreatment ameliorated DMP-777-induced parietal cell loss as well as foveolar hyperplasia." | 1.33 | Omeprazole treatment ameliorates oxyntic atrophy induced by DMP-777. ( Car, BD; Goldenring, JR; Nomura, S; Ogawa, M, 2006) |
| "Pantoprazole is an important drug in the treatment of acid-related disorders." | 1.33 | Preparation, characterization, and in vivo anti-ulcer evaluation of pantoprazole-loaded microparticles. ( Colomé, LM; Guterres, SS; Pohlmann, AR; Raffin, RP, 2006) |
| " This method was suitable for use in pharmacokinetic studies in human volunteers, and provides a useful tool for measuring CYP2C19 activity." | 1.33 | Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes. ( Niioka, T; Shimizu, M; Sugawara, K; Takahata, T; Tateishi, T; Uno, T; Yaui-Furukori, N, 2006) |
| "Rabeprazole was stable in human plasma for 4 months at -70 +/- 5 degrees C and for 20." | 1.32 | Direct injection, column switching-liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study. ( Gupta, S; Jain, M; Lohray, BB; Shah, H; Shah, R; Singh, SS; Thakker, P, 2004) |
| " The proposed method was applied to the determination of rabeprazole in the tablet dosage form." | 1.32 | Voltammetric behaviour of rabeprazole at a glassy carbon electrode and its determination in tablet dosage form. ( Abd El-Ghany, N; Radi, A; Wahdan, T, 2004) |
| "The omeprazole enantiomers were eluted from the RAM column onto an amylose tris(3,5-dimethylphenylcarbamate) chiral column by the use of a column-switching valve and the enantioseparation was performed using acetonitrile-water (60:40 v/v) as eluent." | 1.32 | Enantiomeric determination of the plasma levels of omeprazole by direct plasma injection using high-performance liquid chromatography with achiral-chiral column-switching. ( Cass, QB; Cassiano, NM; Degani, AL; Lima, VV; Oliveira, RV; Pedrazzoli, J, 2003) |
| " Dosage of omeprazole used was 1." | 1.31 | Clinical efficacy of proton pump inhibitor therapy in neurologically impaired children with gastroesophageal reflux: prospective study. ( Chan, KH; Chan, YC; Cheung, KM; Ko, CH; Leung, CY; Tse, PW, 2001) |
| "[14C]Urea breath tests were performed in 20 H." | 1.30 | Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test. ( El-Nujumi, A; Hilditch, TE; McColl, KE; Williams, C, 1998) |
| "The other two approaches prevent more recurrences: waiting to initiate maintenance therapy until symptoms recur once requires an additional $73 for each recurrence prevented whereas maintenance PPI from the outset requires an additional $819 for each recurrence prevented." | 1.30 | Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. ( Harris, RA; Kuppermann, M; Richter, JE, 1997) |
| "Both omeprazole and endoscopy were compared to pH monitoring as the 'gold standard' for the diagnosis of GERD and the cost per correct diagnosis with omeprazole was pound47 (95% CI: pound40- pound59) compared to pound480 (95% CI: pound396- pound608) with endoscopy." | 1.30 | Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. ( Bate, CM; Chapman, RW; Durnin, AT; Riley, SA; Taylor, MD, 1999) |
| "Cytology from Barrett's esophagus can be misleading in the presence of severe inflammation." | 1.30 | Brush cytology in the diagnosis of neoplasia in Barrett's esophagus. ( Alderson, D; Hardwick, RH; Lott, M; Morgan, RJ; Warren, BF, 1997) |
| "Flunitrazepam was used as an internal standard." | 1.30 | Determination of omeprazole in human plasma by high-performance liquid chromatography. ( Klíma, J; Macek, J; Ptácek, P, 1997) |
| "If patients experience a symptomatic recurrence on the H2RA strategies, they then receive PPI maintenance." | 1.30 | Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis. ( Harris, RA; Kuppermann, M; Richter, JE, 1997) |
| " Efficacy estimates were extremely sensitive to changes in quality of life associated with postoperative symptoms and long-term use of medication." | 1.30 | Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. ( Centor, RM; Heudebert, GR; Marks, R; Wilcox, CM, 1997) |
| "Two different ultraviolet (UV) spectroscopic methods were developed for determination of Lansoprazole in pharmaceutical dosage forms." | 1.30 | Determination of Lansoprazole in pharmaceutical dosage forms by two different spectroscopic methods. ( Ozaltín, N, 1999) |
| "Documenting abnormal gastroesophageal reflux helps direct appropriate therapy, and proximal pH monitoring may identify patients with pulmonary symptoms who respond to anti-reflux therapy." | 1.29 | Pulmonary symptoms associated with gastroesophageal reflux: use of ambulatory pH monitoring to diagnose and to direct therapy. ( Castell, DO; Castell, JA; Schnatz, PF, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 37 (32.17) | 18.2507 |
| 2000's | 71 (61.74) | 29.6817 |
| 2010's | 6 (5.22) | 24.3611 |
| 2020's | 1 (0.87) | 2.80 |
| Authors | Studies |
|---|---|
| Eagles, SK | 1 |
| Wang, X | 1 |
| Gross, AS | 1 |
| McLachlan, AJ | 1 |
| Shah, P | 1 |
| Singh, MH | 1 |
| Yang, YX | 1 |
| Metz, DC | 1 |
| Garrean, CP | 1 |
| Zhang, Q | 1 |
| Gonsalves, N | 1 |
| Hirano, I | 1 |
| Apostolou, C | 1 |
| Dotsikas, Y | 1 |
| Kousoulos, C | 1 |
| Loukas, YL | 1 |
| Kuloğlu, Z | 1 |
| Kansu, A | 1 |
| Kirsaçlioğlu, CT | 1 |
| Ustündağ, G | 1 |
| Aysev, D | 1 |
| Ensari, A | 1 |
| Küçük, NO | 1 |
| Girgin, N | 1 |
| Guan, J | 1 |
| Yang, J | 1 |
| Li, J | 1 |
| Li, X | 1 |
| Li, F | 2 |
| Vittal, S | 1 |
| Ganneboina, R | 1 |
| Layek, B | 1 |
| Trivedi, RK | 1 |
| Hotha, KK | 2 |
| Bharathi, DV | 2 |
| Mullangi, R | 2 |
| Rambla-Alegre, M | 1 |
| Esteve-Romero, J | 1 |
| Carda-Broch, S | 1 |
| Ishiyama, F | 1 |
| Iijima, K | 1 |
| Asanuma, K | 1 |
| Ara, N | 1 |
| Yoshitake, J | 1 |
| Abe, Y | 1 |
| Koike, T | 1 |
| Imatani, A | 1 |
| Ohara, S | 1 |
| Shimosegawa, T | 1 |
| Jagadeesh, B | 1 |
| Chatki, PK | 1 |
| Thriveni, K | 1 |
| Naidu, A | 1 |
| Zhang, W | 1 |
| Han, F | 1 |
| Guo, P | 1 |
| Zhao, H | 1 |
| Lin, ZJ | 1 |
| Huang, MQ | 1 |
| Bertelsen, K | 1 |
| Weng, N | 1 |
| de Leone, A | 1 |
| Tonini, M | 1 |
| Dominici, P | 1 |
| Grossi, E | 1 |
| Pace, F | 1 |
| Ha, JJ | 1 |
| Choi, HJ | 1 |
| Jin, JS | 1 |
| Jeong, ED | 1 |
| Hyun, MH | 1 |
| Liu, G | 1 |
| Snapp, HM | 1 |
| Ji, QC | 1 |
| Shiohira, H | 1 |
| Yasui-Furukori, N | 2 |
| Tateishi, T | 3 |
| Uno, T | 3 |
| Pandak, WM | 1 |
| Arezo, S | 1 |
| Everett, S | 1 |
| Jesse, R | 1 |
| DeCosta, G | 1 |
| Crofts, T | 1 |
| Gennings, C | 1 |
| Siuta, M | 1 |
| Zfass, A | 1 |
| González, HM | 1 |
| Romero, EM | 1 |
| Chavez, Tde J | 1 |
| Peregrina, AA | 1 |
| Quezada, V | 1 |
| Hoyo-Vadillo, C | 1 |
| Kawai, T | 1 |
| Kawakami, K | 1 |
| Kudo, T | 1 |
| Ogiahara, S | 1 |
| Handa, Y | 1 |
| Moriyasu, F | 1 |
| Oliveira, CH | 1 |
| Barrientos-Astigarraga, RE | 1 |
| Abib, E | 1 |
| Mendes, GD | 1 |
| da Silva, DR | 1 |
| de Nucci, G | 1 |
| Dulbecco, P | 1 |
| Gambaro, C | 1 |
| Bilardi, C | 1 |
| Zentilin, P | 1 |
| Mele, MR | 1 |
| Mansi, C | 1 |
| Biagini, R | 1 |
| Tessieri, L | 1 |
| Iiritano, E | 1 |
| Usai, P | 1 |
| Vigneri, S | 1 |
| Savarino, V | 1 |
| Skoczylas, T | 1 |
| Sarosiek, I | 1 |
| Sostarich, S | 1 |
| McElhinney, C | 1 |
| Durham, S | 1 |
| Sarosiek, J | 1 |
| Gardner, JD | 1 |
| Sloan, S | 1 |
| Miner, PB | 1 |
| Robinson, M | 1 |
| Matsuda, M | 1 |
| Noda, Y | 1 |
| Takemori, Y | 1 |
| Radi, A | 2 |
| Johnsson, F | 3 |
| Hatlebakk, JG | 1 |
| Klintenberg, AC | 1 |
| Román, J | 1 |
| Toth, E | 1 |
| Stubberöd, A | 1 |
| Falk, A | 1 |
| Edin, R | 1 |
| Gisbert, JP | 1 |
| Ducons, J | 1 |
| Gomollón, F | 1 |
| Domínguez-Muñoz, JE | 1 |
| Borda, F | 1 |
| Miño, G | 1 |
| Jiménez, I | 1 |
| Vázquez, MA | 1 |
| Santolaria, S | 1 |
| Gallego, S | 1 |
| Iglesias, J | 1 |
| Pastor, G | 1 |
| Hervás, A | 1 |
| Pajares, JM | 1 |
| Orlando, RM | 1 |
| Bonato, PS | 1 |
| Cass, QB | 2 |
| Lima, VV | 1 |
| Oliveira, RV | 1 |
| Cassiano, NM | 2 |
| Degani, AL | 2 |
| Pedrazzoli, J | 1 |
| Jensen, BP | 1 |
| Smith, C | 1 |
| Wilson, ID | 1 |
| Weidolf, L | 1 |
| Juul-Hansen, P | 1 |
| Rydning, A | 1 |
| Miura, M | 1 |
| Tada, H | 1 |
| Suzuki, T | 1 |
| Bautista, J | 1 |
| Fullerton, H | 1 |
| Briseno, M | 1 |
| Cui, H | 2 |
| Fass, R | 6 |
| Saribas, S | 1 |
| Kocazeybek, B | 1 |
| Aslan, M | 1 |
| Altun, S | 1 |
| Seyhun, Y | 1 |
| Öner, YA | 1 |
| Memisoglu, N | 1 |
| Abd El-Ghany, N | 1 |
| Wahdan, T | 1 |
| Jerdi, MC | 1 |
| Daali, Y | 1 |
| Oestreicher, MK | 1 |
| Cherkaoui, S | 1 |
| Dayer, P | 1 |
| Yeniceli, D | 1 |
| Dogrukol-Ak, D | 1 |
| Tuncel, M | 1 |
| Asfeldt, AM | 1 |
| Løchen, ML | 1 |
| Straume, B | 1 |
| Steigen, SE | 1 |
| Florholmen, J | 1 |
| Goll, R | 1 |
| Nestegard, O | 1 |
| Paulssen, EJ | 1 |
| Singh, SS | 1 |
| Jain, M | 1 |
| Shah, H | 1 |
| Gupta, S | 1 |
| Thakker, P | 1 |
| Shah, R | 1 |
| Lohray, BB | 1 |
| Plante, L | 1 |
| Ferron, GM | 1 |
| Unruh, M | 1 |
| Mayer, PR | 1 |
| Ramakrishna, NV | 2 |
| Vishwottam, KN | 2 |
| Wishu, S | 2 |
| Koteshwara, M | 2 |
| Kumar, SS | 1 |
| Takahata, T | 2 |
| Sugawara, K | 2 |
| Mana, F | 1 |
| Van Laer, W | 1 |
| Van Laere, W | 1 |
| Bossuyt, A | 1 |
| Urbain, D | 1 |
| Taghavi, SA | 1 |
| Ghasedi, M | 1 |
| Saberi-Firoozi, M | 1 |
| Alizadeh-Naeeni, M | 1 |
| Bagheri-Lankarani, K | 1 |
| Kaviani, MJ | 1 |
| Hamidpour, L | 1 |
| Wang, J | 1 |
| Wang, Y | 2 |
| Fawcett, JP | 1 |
| Gu, J | 1 |
| Huang, J | 1 |
| Xu, Y | 1 |
| Gao, S | 1 |
| Rui, L | 1 |
| Guo, Q | 1 |
| Dickman, R | 1 |
| Emmons, S | 1 |
| Sewell, J | 1 |
| Hernández, D | 1 |
| Esquivel, RF | 1 |
| Song, Q | 1 |
| Naidong, W | 1 |
| Hofmann, U | 1 |
| Schwab, M | 1 |
| Treiber, G | 1 |
| Klotz, U | 1 |
| Shimizu, M | 1 |
| Niioka, T | 1 |
| Yaui-Furukori, N | 1 |
| Garcia, CV | 1 |
| Paim, CS | 1 |
| Steppe, M | 1 |
| Schapoval, EE | 1 |
| Raffin, RP | 1 |
| Colomé, LM | 1 |
| Pohlmann, AR | 1 |
| Guterres, SS | 1 |
| Ogawa, M | 1 |
| Nomura, S | 1 |
| Car, BD | 1 |
| Goldenring, JR | 1 |
| des Varannes, SB | 1 |
| Sacher-Huvelin, S | 1 |
| Vavasseur, F | 1 |
| Masliah, C | 1 |
| Le Rhun, M | 1 |
| Aygalenq, P | 1 |
| Bonnot-Marlier, S | 1 |
| Lequeux, Y | 1 |
| Galmiche, JP | 1 |
| Jia, H | 1 |
| Li, W | 1 |
| Zhao, K | 1 |
| Vaezi, MF | 1 |
| Liu, P | 1 |
| Sun, B | 1 |
| Lu, X | 1 |
| Qin, F | 1 |
| Macek, J | 2 |
| Klíma, J | 2 |
| Ptácek, P | 2 |
| Tepes, B | 1 |
| Nirogi, R | 1 |
| Kandikere, V | 1 |
| Mudigonda, K | 1 |
| Bhyrapuneni, G | 1 |
| Chey, WD | 2 |
| Spybrook, M | 1 |
| Carpenter, S | 1 |
| Nostrant, TT | 1 |
| Elta, GH | 1 |
| Scheiman, JM | 1 |
| Harding, SM | 1 |
| Richter, JE | 5 |
| Guzzo, MR | 1 |
| Schan, CA | 1 |
| Alexander, RW | 1 |
| Bradley, LA | 1 |
| Shimoyama, T | 2 |
| Fukuda, Y | 1 |
| Fukuda, S | 1 |
| Munakata, A | 1 |
| Yoshida, Y | 1 |
| Schnatz, PF | 1 |
| Castell, JA | 1 |
| Castell, DO | 1 |
| Heudebert, GR | 1 |
| Marks, R | 1 |
| Wilcox, CM | 1 |
| Centor, RM | 1 |
| Kim, MJ | 1 |
| Michener, R | 1 |
| Triadafilopoulos, G | 1 |
| Harris, RA | 2 |
| Kuppermann, M | 2 |
| Sarker, SA | 1 |
| Mahalanabis, D | 1 |
| Bardhan, PK | 1 |
| Alam, NH | 1 |
| Rabbani, KS | 1 |
| Kiber, A | 1 |
| Hassan, M | 1 |
| Islam, S | 1 |
| Fuchs, GJ | 1 |
| Gyr, K | 1 |
| Lévy, M | 1 |
| Hammel, P | 1 |
| Lamarque, D | 1 |
| Marty, O | 1 |
| Chaumette, MT | 1 |
| Haioun, C | 1 |
| Blazquez, M | 1 |
| Delchier, JC | 1 |
| Schenk, BE | 1 |
| Kuipers, EJ | 1 |
| Klinkenberg-Knol, EC | 1 |
| Festen, HP | 1 |
| Jansen, EH | 1 |
| Tuynman, HA | 1 |
| Schrijver, M | 1 |
| Dieleman, LA | 1 |
| Meuwissen, SG | 1 |
| Hicks, DM | 1 |
| Hardwick, RH | 1 |
| Morgan, RJ | 1 |
| Warren, BF | 1 |
| Lott, M | 1 |
| Alderson, D | 1 |
| Weywadt, L | 1 |
| Solhaug, JH | 1 |
| Hernqvist, H | 1 |
| Bengtsson, L | 1 |
| Laine, L | 2 |
| Suchower, L | 2 |
| Johnson, E | 1 |
| Ronca, P | 1 |
| Neil, G | 2 |
| Fennerty, MB | 4 |
| Ofman, JJ | 4 |
| Gralnek, IM | 3 |
| Johnson, C | 2 |
| Camargo, E | 2 |
| Sampliner, RE | 3 |
| Gismondo, MR | 1 |
| Drago, L | 1 |
| Lombardi, A | 1 |
| Fassina, MC | 1 |
| Mombelli, B | 1 |
| Perri, F | 1 |
| Clemente, R | 1 |
| Festa, V | 1 |
| Quitadamo, M | 1 |
| Conoscitore, P | 1 |
| Niro, G | 1 |
| Ghoos, Y | 1 |
| Rutgeerts, P | 1 |
| Andriulli, A | 1 |
| Tanahashi, T | 1 |
| Kodama, T | 1 |
| Yamaoka, Y | 1 |
| Sawai, N | 1 |
| Tatsumi, Y | 1 |
| Kashima, K | 1 |
| Higashi, Y | 1 |
| Sasaki, Y | 1 |
| Coudron, PE | 1 |
| Stratton, CW | 1 |
| Yeung, PK | 1 |
| Little, R | 1 |
| Jiang, Y | 1 |
| Buckley, SJ | 1 |
| Pollak, PT | 1 |
| Kapoor, H | 1 |
| Veldhuyzen van Zanten, SJ | 1 |
| Carlsson, R | 1 |
| Dent, J | 1 |
| Bolling-Sternevald, E | 1 |
| Junghard, O | 2 |
| Lauritsen, K | 2 |
| Riley, S | 1 |
| Lundell, L | 1 |
| El-Nujumi, A | 1 |
| Hilditch, TE | 1 |
| Williams, C | 1 |
| McColl, KE | 1 |
| Bate, CM | 1 |
| Riley, SA | 1 |
| Chapman, RW | 1 |
| Durnin, AT | 1 |
| Taylor, MD | 1 |
| Woolf, EJ | 1 |
| Matuszewski, BK | 1 |
| Talley, NJ | 1 |
| Wiklund, IK | 1 |
| Badia, X | 1 |
| Segú, JL | 1 |
| Ollé, A | 1 |
| Brosa, M | 1 |
| Monés, J | 1 |
| García Ponte, L | 1 |
| Bravo, LE | 1 |
| Realpe, JL | 1 |
| Campo, C | 1 |
| Mera, R | 1 |
| Correa, P | 1 |
| Udani, J | 1 |
| Connor, SJ | 1 |
| Seow, F | 1 |
| Ngu, MC | 1 |
| Katelaris, PH | 1 |
| Irwin, RS | 1 |
| Zawacki, JK | 1 |
| Stenhoff, H | 1 |
| Blomqvist, A | 1 |
| Lagerström, PO | 1 |
| Miyabayashi, H | 1 |
| Furihata, K | 1 |
| Shimizu, T | 1 |
| Ueno, I | 1 |
| Akamatsu, T | 1 |
| Ladas, SD | 1 |
| Tassios, PS | 1 |
| Raptis, SA | 1 |
| Ozaltín, N | 2 |
| Camargo, L | 1 |
| Wendel, C | 1 |
| Sugg, J | 1 |
| Romero Gómez, M | 1 |
| Vargas, J | 1 |
| Grande, L | 1 |
| Otero, MA | 1 |
| Bernal, S | 1 |
| Castro Fernández, M | 1 |
| Miwi, H | 1 |
| Murai, T | 1 |
| Sato, K | 1 |
| Ohkura, R | 1 |
| Yamada, T | 1 |
| Nagahara, A | 1 |
| Ohtaka, K | 1 |
| Minowa, T | 1 |
| Kurosawa, A | 1 |
| Sato, N | 1 |
| Fanti, L | 1 |
| Ieri, R | 1 |
| Mezzi, G | 1 |
| Testoni, PA | 1 |
| Passaretti, S | 1 |
| Guslandi, M | 1 |
| Yuen, KH | 1 |
| Choy, WP | 1 |
| Tan, HY | 1 |
| Wong, JW | 1 |
| Yap, SP | 1 |
| Yardimci, C | 1 |
| Chathadi, KV | 1 |
| Montague, J | 1 |
| Ahmed, F | 1 |
| Murthy, U | 1 |
| Katsuki, H | 1 |
| Hamada, A | 1 |
| Nakamura, C | 1 |
| Arimori, K | 1 |
| Nakano, M | 1 |
| O'Boyle, CJ | 1 |
| Watson, DI | 1 |
| Sharma, VK | 1 |
| Sahai, AV | 1 |
| Corder, FA | 1 |
| Howden, CW | 1 |
| Cheung, KM | 1 |
| Tse, PW | 1 |
| Ko, CH | 1 |
| Chan, YC | 1 |
| Leung, CY | 1 |
| Chan, KH | 1 |
| Pedrazolli, J | 1 |
| Parente, F | 1 |
| Sainaghi, M | 1 |
| Sangaletti, O | 1 |
| Imbesi, V | 1 |
| Maconi, G | 1 |
| Anderloni, A | 1 |
| Bianchi Porro, G | 1 |
| Odaka, T | 1 |
| Yamaguchi, T | 1 |
| Koyama, H | 1 |
| Saisho, H | 1 |
| Nomura, F | 1 |
| Nishimura, M | 1 |
| Yoshitsugu, H | 1 |
| Naito, S | 1 |
| Hiraoka, I | 1 |
| Stolte, M | 1 |
| Bethke, B | 1 |
| Rühl, G | 1 |
| Ritter, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Empiric Anti-reflux Therapy in Pediatric Otitis Media With Effusion - a Pilot Study[NCT01082029] | Phase 4 | 65 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Study of a Dietary Supplement for Reflux During Sleep[NCT02274636] | 50 participants (Anticipated) | Interventional | 2014-10-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for omeprazole and Sensitivity and Specificity
| Article | Year |
|---|---|
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infection | 2001 |
26 trials available for omeprazole and Sensitivity and Specificity
| Article | Year |
|---|---|
The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration.
Topics: Adult; Drug Administration Schedule; Esophageal pH Monitoring; Esophagitis; Esophagoscopy; Female; G | 2010 |
Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring.
Topics: Adult; Aged; Anti-Ulcer Agents; Chest Pain; Cross-Over Studies; Diagnosis, Differential; Dose-Respon | 2002 |
Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzimidazoles; Breath Tests; Dose-Response Relations | 2003 |
Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Analysis of Variance; Benzimidazoles; Cross-Over Stu | 2003 |
Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cross-Over Studies; Gast | 2003 |
One-week esomeprazole treatment: an effective confirmatory test in patients with suspected gastroesophageal reflux disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Endoscopy, Gastrointestinal; Esomeprazole; Fema | 2003 |
Validation of the 13c-urea breath test for the initial diagnosis of helicobacter pylori infection and to confirm eradication after treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Carbon Isotopes; Clarith | 2003 |
Endoscopy-negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Endoscopy, Gastrointestinal | 2003 |
The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chest Pa | 2004 |
The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Chest Pain; | 2005 |
Rabeprazole test for the diagnosis of gastro-oesophageal reflux disease: results of a study in a primary care setting.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2006 |
Endoscopic ultrasonography for the initial staging and follow-up in patients with low-grade gastric lymphoma of mucosa-associated lymphoid tissue treated medically.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Antineoplastic Agents, Alkylating; Clarithromycin; | 1997 |
Omeprazole as a diagnostic tool in gastroesophageal reflux disease.
Topics: Adult; Aged; Chi-Square Distribution; Double-Blind Method; Female; Gastric Acidity Determination; Ga | 1997 |
One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Esophagoscopy; Female; Gastroesophageal Reflux; H | 1998 |
Accuracy of CLOtest after Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulc | 1998 |
The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain.
Topics: Adult; Aged; Aged, 80 and over; Chest Pain; Double-Blind Method; Enzyme Inhibitors; Female; Gastroes | 1998 |
Relationship between the results of pre-treatment urea breath test and efficacy of eradication of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Drug Admin | 1998 |
Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non ulcer dyspepsia.
Topics: Analysis of Variance; Diet Records; Double-Blind Method; Dyspepsia; Enzyme Inhibitors; Female; Human | 1998 |
Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease.
Topics: Adult; Aged; Anti-Ulcer Agents; Arizona; Cost-Benefit Analysis; Cross-Over Studies; Diagnosis, Diffe | 1999 |
The effect of dosing with omeprazole on the accuracy of the 13C-urea breath test in Helicobacter pylori-infected subjects.
Topics: Adult; Anti-Ulcer Agents; Breath Tests; Carbon Radioisotopes; False Negative Reactions; Female; Heli | 1999 |
Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromy | 2000 |
Endoscopic biopsy requirements for post-treatment diagnosis of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Double-Blind Method; | 2000 |
Comparison of the efficacy of 400mg and 800mg of clarithromycin used with lansoprazole and amoxicillin in eradication regimens for Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2000 |
Long-term follow-up and serologic assessment after triple therapy with omeprazole or lansoprazole of Helicobacter-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies | 2001 |
Long-term management of gastro-eosophageal reflux disease with omeprazole or open antireflux surgery.
Topics: Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fundoplication; Gastroesophageal Reflux | 2001 |
Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Breath Tests; Car | 2002 |
88 other studies available for omeprazole and Sensitivity and Specificity
| Article | Year |
|---|---|
An improved cytochrome P450 phenotyping cocktail with a simplified and highly sensitive UHPLC-MS/MS assay in human plasma.
Topics: Biosensing Techniques; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Syste | 2020 |
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Fe | 2013 |
Acid reflux detection and symptom-reflux association using 4-day wireless pH recording combining 48-hour periods off and on PPI therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Esophageal pH Monitoring; F | 2008 |
Development and validation of an improved high-throughput method for the determination of anastrozole in human plasma by LC-MS/MS and atmospheric pressure chemical ionization.
Topics: Acetonitriles; Anastrozole; Area Under Curve; Aromatase Inhibitors; Atmospheric Pressure; Chromatogr | 2008 |
A rapid lateral flow stool antigen immunoassay and (14)C-urea breath test for the diagnosis and eradication of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Breath Tests | 2008 |
Determination of tenatoprazole enantiomers and their enantioselective pharmacokinetics in rats.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; Chromatography, High Pressur | 2009 |
Highly sensitive method for the determination of omeprazole in human plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a clinical pharmacokinetic study.
Topics: Analytic Sample Preparation Methods; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Enzyme | 2009 |
Analysis of omeprazole and its main metabolites by liquid chromatography using hybrid micellar mobile phases.
Topics: 1-Propanol; Anti-Ulcer Agents; Chromatography, Liquid; Humans; Omeprazole; Pharmaceutical Preparatio | 2009 |
Exogenous luminal nitric oxide exacerbates esophagus tissue damage in a reflux esophagitis model of rats.
Topics: Analysis of Variance; Animals; Ascorbic Acid; Biopsy, Needle; Disease Models, Animal; Dose-Response | 2009 |
Simultaneous estimation of four proton pump inhibitors--lansoprazole, omeprazole, pantoprazole and rabeprazole: development of a novel generic HPLC-UV method and its application to clinical pharmacokinetic study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Drug Stability; Human | 2009 |
Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions.
Topics: Chromatography, Liquid; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Discovery; Drug Inter | 2010 |
Liquid chromatographic resolution of proton pump inhibitors including omeprazole on a ligand exchange chiral stationary phase.
Topics: Acetonitriles; Chromatography, Liquid; Copper Sulfate; Ethylamines; Hydrogen-Ion Concentration; Omep | 2010 |
Internal standard tracked dilution to overcome challenges in dried blood spots and robotic sample preparation for liquid chromatography/tandem mass spectrometry assays.
Topics: Blood Specimen Collection; Chromatography, Liquid; Humans; Models, Chemical; Omeprazole; Reference S | 2011 |
Chiral assay of omeprazole and metabolites and its application to a pharmacokinetics related to CYP2C19 genotypes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressur | 2011 |
Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction.
Topics: Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytoc | 2002 |
A new serum antibody test kit (E plate) for evaluation of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
Lansoprazole quantification in human plasma by liquid chromatography-electrospray tandem mass spectrometry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Chromatography, Liquid; Humans; Lansopra | 2003 |
Utility and limitations of a method for detecting Helicobacter pylori-specific antigens in the stool.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antigens, Bact | 2003 |
Anodic voltammetric assay of lansoprazole and omeprazole on a carbon paste electrode.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Capsules; Lansoprazole; Omeprazole; Polarography; Proton Pu | 2003 |
Simple and efficient method for enantioselective determination of omeprazole in human plasma.
Topics: Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Humans; Omeprazole; Reproducibility of Resu | 2003 |
Enantiomeric determination of the plasma levels of omeprazole by direct plasma injection using high-performance liquid chromatography with achiral-chiral column-switching.
Topics: Anti-Ulcer Agents; Area Under Curve; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Humans | 2003 |
Sensitive sulphur-specific detection of omeprazole metabolites in rat urine by high-performance liquid chromatography/inductively coupled plasma mass spectrometry.
Topics: Animals; Chromatography, High Pressure Liquid; Male; Mass Spectrometry; Molecular Structure; Omepraz | 2004 |
Simultaneous determination of lansoprazole enantiomers and their metabolites in plasma by liquid chromatography with solid-phase extraction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Humans; Kidney Transp | 2004 |
Do procalcitonin and C-reactive protein levels have a place in the diagnosis and follow-up of Helicobacter pylori infections?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biomarkers; Biopsy; C-Reactive Protein; Calcitonin; | 2004 |
Voltammetric behaviour of rabeprazole at a glassy carbon electrode and its determination in tablet dosage form.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Carbon; Chromatography, High Pressure Liqui | 2004 |
A simplified analytical method for a phenotyping cocktail of major CYP450 biotransformation routes.
Topics: Biotransformation; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; D | 2004 |
Determination of lansoprazole in pharmaceutical capsules by flow injection analysis using UV-detection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Capsules; Flow Injection Analysis; Lansoprazole; Omeprazole | 2004 |
Accuracy of a monoclonal antibody-based stool antigen test in the diagnosis of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antigens, | 2004 |
Direct injection, column switching-liquid chromatographic technique for the estimation of rabeprazole in bioequivalence study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Calibration; Chromatography, High Pressure | 2004 |
Excretion of pantoprazole in human breast.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Biological Transport, Active; Breast | 2004 |
High-performance liquid chromatography method for the quantification of rabeprazole in human plasma using solid-phase extraction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography, High Pressure Liquid; Drug | 2005 |
Determination of lansoprazole and two of its metabolites by liquid-liquid extraction and automated column-switching high-performance liquid chromatography: application to measuring CYP2C19 activity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Chromatography, High Pressure Liquid; Female; Humans | 2005 |
The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Breath Tests; Carbon Isotopes; Enzyme Inhibitors; Fem | 2005 |
Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole.
Topics: Adult; Drug Administration Schedule; Female; Gastroesophageal Reflux; Heartburn; Humans; Hydrogen-Io | 2005 |
Determination of omeprazole in human plasma by liquid chromatography-electrospray quadrupole linear ion trap mass spectrometry.
Topics: Calibration; Chemistry, Pharmaceutical; Chromatography; Chromatography, High Pressure Liquid; Chroma | 2005 |
High-performance liquid chromatography method for the quantification of pantoprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography, High Pressure Liquid; Human | 2005 |
Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of rabeprazole in human plasma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Calibration; Carbohydrate Sequence; Chromat | 2005 |
Analysis of omeprazole and 5-OH omeprazole in human plasma using hydrophilic interaction chromatography with tandem mass spectrometry (HILIC-MS/MS)--eliminating evaporation and reconstitution steps in 96-well liquid/liquid extraction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, Liquid; Humans; Mass Spectrometry; Omeprazo | 2006 |
Sensitive quantification of omeprazole and its metabolites in human plasma by liquid chromatography-mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Esomeprazole; Gastroesophageal Reflux; Humans; Omeprazole; Sen | 2006 |
Sensitive determination of omeprazole and its two main metabolites in human plasma by column-switching high-performance liquid chromatography: application to pharmacokinetic study in relation to CYP2C19 genotypes.
Topics: Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Femal | 2006 |
Development and validation of a dissolution test for rabeprazole sodium in coated tablets.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Chromatography, High Pressure Liquid; Hydro | 2006 |
Preparation, characterization, and in vivo anti-ulcer evaluation of pantoprazole-loaded microparticles.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Benzimidazoles; Calorimetry, Di | 2006 |
Omeprazole treatment ameliorates oxyntic atrophy induced by DMP-777.
Topics: Analysis of Variance; Animals; Azetidines; Disease Models, Animal; Drug Interactions; Gastric Acid; | 2006 |
Determination of omeprazole in rat plasma by high-performance liquid chromatography without solvent extraction.
Topics: Animals; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Male; Omeprazole; Rats; Rats, Wist | 2006 |
Should we bravo?
Topics: Cohort Studies; Equipment Design; Equipment Safety; Esophageal pH Monitoring; Esophagoscopy; Female; | 2006 |
HPLC determination and pharmacokinetic study of tenatoprazole in dog plasma after oral administration of enteric-coated capsule.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Animals; Calibration; Capsules; Chrom | 2007 |
Rapid determination of omeprazole in human plasma by protein precipitation and liquid chromatography-tandem mass spectrometry.
Topics: Anti-Ulcer Agents; Blood Proteins; Chemical Precipitation; Chromatography, High Pressure Liquid; Enz | 2007 |
Comparison of two invasive diagnostic tests for Helicobacter pylori after antimicrobial therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combina | 2007 |
Quantification of tenatoprazole in rat plasma by HPLC: validation and its application to pharmacokinetic studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Chromatography, High Pressure Liquid; Imidazoles; | 2007 |
Prolonged effect of omeprazole on the 14C-urea breath test.
Topics: Anti-Bacterial Agents; Breath Tests; Carbon Radioisotopes; Dose-Response Relationship, Drug; False N | 1996 |
Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome.
Topics: Adult; Aged; Anti-Ulcer Agents; Asthma; Barium Sulfate; Contrast Media; Esophagus; Female; Forced Ex | 1996 |
Validity of various diagnostic tests to evaluate cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Bacteriological Techniq | 1996 |
Pulmonary symptoms associated with gastroesophageal reflux: use of ambulatory pH monitoring to diagnose and to direct therapy.
Topics: Anti-Ulcer Agents; Asthma; Cough; Esophagus; Female; Gastroesophageal Reflux; Histamine H2 Antagonis | 1996 |
Determination of omeprazole in human plasma by high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Flunitrazepam; Humans; Indicators and Reagents | 1997 |
Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis.
Topics: Adult; Cost-Benefit Analysis; Esophagitis; Fundoplication; Health Care Costs; Humans; Markov Chains; | 1997 |
Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment.
Topics: Amoxicillin; Bicarbonates; Bismuth; Carbon Isotopes; Clarithromycin; Drug Therapy, Combination; Gast | 1997 |
Prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cost-Benefit Analysis; Esophagitis, Pept | 1997 |
Noninvasive assessment of gastric acid secretion in man. Application of electrical impedance tomography (EIT).
Topics: Adolescent; Adult; Anti-Ulcer Agents; Electric Impedance; Gastric Acid; Humans; Omeprazole; Pentagas | 1997 |
Unresolved issues in gastroesophageal reflux-related ear, nose, and throat problems.
Topics: Animals; Anti-Ulcer Agents; Esophagus; Gastric Acid; Gastroesophageal Reflux; Humans; Hydrogen-Ion C | 1997 |
Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Case-Control Studies; Cost-Benefit Analy | 1997 |
Brush cytology in the diagnosis of neoplasia in Barrett's esophagus.
Topics: Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Cell Count; Cell Nucleus; Chromatin; C | 1997 |
Interference on Helicobacter pylori growth and adhesion by omeprazole and other drugs.
Topics: Anti-Ulcer Agents; Bacterial Adhesion; Helicobacter pylori; Humans; Microbial Sensitivity Tests; Ome | 1998 |
Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cl | 1998 |
The bactericidal activity of clarithromycin versus ampicillin alone and in combination with omeprazole and/or bismuth against clarithromycin-susceptible and clarithromycin-resistant strains of Helicobacter pylori.
Topics: Ampicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions; Drug Resistance, Micr | 1998 |
A simple high performance liquid chromatography assay for simultaneous determination of omeprazole and metronidazole in human plasma and gastric fluid.
Topics: Anti-Infective Agents; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Gastric Juice; Human | 1998 |
The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease.
Topics: Anti-Ulcer Agents; Dyspepsia; Endoscopy, Digestive System; Esophagitis, Peptic; Gastric Acidity Dete | 1998 |
Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test.
Topics: Anti-Ulcer Agents; Antigens, Bacterial; Breath Tests; Dyspepsia; False Negative Reactions; False Pos | 1998 |
Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Enzyme I | 1999 |
Simultaneous determination of omeprazole and 5'-hydroxyomeprazole in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chromatography, High Pressure Liquid; Humans; Mass Spectrom | 1998 |
Cost-effectiveness analysis of different strategies for treating duodenal ulcer. Helicobacter pylori eradication versus antisecretory treatment.
Topics: Anti-Ulcer Agents; Cost-Benefit Analysis; Duodenal Ulcer; Helicobacter pylori; Humans; Markov Chains | 1997 |
Effects of acid suppression and bismuth medications on the performance of diagnostic tests for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antigens, Bacterial; Bismuth; Breath Tes | 1999 |
The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain.
Topics: Anti-Ulcer Agents; Chest Pain; Cost-Benefit Analysis; Decision Trees; Diagnosis, Differential; Esoph | 1999 |
Cost-effectiveness of testing for gastroesophageal reflux disease: what do patients, physicians, and health insurers want?
Topics: Anti-Ulcer Agents; Chest Pain; Cost-Benefit Analysis; Diagnosis, Differential; Esophagoscopy; Gastro | 1999 |
Accurately diagnosing and successfully treating chronic cough due to gastroesophageal reflux disease can be difficult.
Topics: Antacids; Asthma; Chronic Disease; Consensus Development Conferences as Topic; Cough; Diagnosis, Dif | 1999 |
Determination of the enantiomers of omeprazole in blood plasma by normal-phase liquid chromatography and detection by atmospheric pressure ionization tandem mass spectrometry.
Topics: Anti-Ulcer Agents; Chromatography, Liquid; Humans; Mass Spectrometry; Omeprazole; Quality Control; S | 1999 |
Selection of patients for successful maintenance treatment of esophagitis with low-dose omeprazole: use of 24-hour gastric pH monitoring.
Topics: Adult; Aged; Confidence Intervals; Enzyme Inhibitors; Esophagitis, Peptic; Esophagoscopy; Female; Fo | 2000 |
Determination of Lansoprazole in pharmaceutical dosage forms by two different spectroscopic methods.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Calibration; Capsules; Evaluation Studie | 1999 |
The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Esophagitis; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion C | 2000 |
[Usefulness of Helicobacter pylori antigen detection in stools in the diagnosis of infection and confirming eradication after treatment].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Antigens, | 2000 |
Improved high performance liquid chromatographic analysis of omeprazole in human plasma.
Topics: Chloramphenicol; Chromatography, High Pressure Liquid; Humans; Omeprazole; Sensitivity and Specifici | 2001 |
Electrochemical studies and differential pulse polarographic analysis of lansoprazole in pharmaceuticals.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Calibration; Capsules; Lansoprazole; Ome | 2001 |
Intragastric acidification reduces the occurrence of false-negative urea breath test results in patients taking a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Breath Tests; False Negative Reactions; Female; Gastric Aci | 2001 |
High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Calibration; Chromatography, High Pressure Liquid; Humans; | 2001 |
Clinical efficacy of proton pump inhibitor therapy in neurologically impaired children with gastroesophageal reflux: prospective study.
Topics: Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Gastroesophageal R | 2001 |
Enantiomeric determination of pantoprazole in human plasma by multidimensional high-performance liquid chromatography.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Calibration; Chromatography, High Pressure | 2002 |
Evaluation of the Helicobacter pylori stool antigen test for monitoring eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2002 |
Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR.
Topics: Aged; Alcohol Dehydrogenase; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP-Binding Ca | 2002 |
Omeprazole-induced pseudohypertrophy of gastric parietal cells.
Topics: Cell Membrane; Cytological Techniques; Gastric Mucosa; Humans; Hypertrophy; Omeprazole; Parietal Cel | 1992 |